Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors

Abstract

Purpose:

To investigate the incidence of immune-related adverse events (irAEs) of immune checkpoint inhibitor (ICI) therapy and to report the clinical features, management, and outcomes of ophthalmic irAEs.

Methods:

We retrospectively reviewed the medical records of patients who received ICI therapy from January 2016 to September 2022 at Peking Union Medical College Hospital and analyzed the incidence of systemic and ophthalmic adverse effects of this therapy.

Results:

Of 962 patients, 248 (25.8%) experienced irAEs. The first-year incidences of total irAEs and ophthalmic irAEs were 23.5% and 1.1%. The most common ICI received by the patients was pembrolizumab (373; 38.8%). Nearly half of the patients (477; 49.6%) had lung cancer. Combination therapy was associated with an increased incidence of irAEs without statistical significance. Patients with lung cancer presented with an increased incidence of total irAEs (p = 0.003) and ophthalmic irAEs (p = 0.032). Eleven patients had ophthalmic manifestations, including ophthalmoplegia (6/11), conjunctivitis (3/11), reactive cutaneous capillary endothelial proliferation (RCCEP) (1/11), and orbital inflammation (1/11). Eight patients had concomitant extra-ophthalmic irAEs. Furthermore, ICIs were discontinued in nine patients, and most ophthalmic manifestations were well controlled with topical and systemic steroids. Ten patients were treated with intravenous or oral steroids. However, cancer progression occurred in five out of eleven patients after the interruption of ICIs.

Conclusion:

IrAEs are correlated with ICI regimens and underlying neoplasia. In our Chinese cohort, patients have a higher risk of ophthalmoplegia than uveitis. Early recognition and multidisciplinary consultation are crucial for optimal treatment of ophthalmic irAEs.

Introduction

Immune checkpoint inhibitor (ICI) therapy has become the first choice for patients with advanced cancer. The targets of currently approved ICIs include programed cell death-1 protein (PD-1), programed cell death ligand-1 protein (PD-L1), and cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) (1). By blocking these pathways using monoclonal antibodies, cytotoxic T cells can be activated to destroy tumor cells. However, overactivation of T cell function also leads to autoimmune toxicities in other organs, known as immune-related adverse events (irAEs). These adverse events can affect almost all organs, including the eye, orbit, and ocular adnexa.

The severity of irAEs range from mild to severe. Ophthalmic irAEs have a relatively low frequency. Approximately 2.8–7.4% of patients receiving ICI therapy experience ophthalmic irAEs (2–5). Although ophthalmic irAEs are usually low-grade and not life-threatening compared with irAEs of other systems, such as myocarditis, they can sometimes severely impact patients’ visual function and cause deterioration in their quality of life (1, 6). However, many patients do not receive timely and appropriate ophthalmic treatment because of insufficient attention. This is because, despite being reported as serious irAEs, only 64% of patients with ophthalmic manifestations are evaluated by ophthalmologists (5). Although most ophthalmic irAEs are well controlled by local and/or oral glucocorticoids (GCs), early recognition and appropriate therapeutic intervention are essential to prevent permanent vision loss, and avoid discontinuation of life-prolonging ICI therapy.

Most data in the literature were based on the White populations (2, 3, 7).In this study, we aim to report the incidence of irAEs, specifically ophthalmic irAEs, in a large group of Chinese patients receiving ICI therapy. Clinical features, management, and outcomes of ophthalmic irAEs are also described.

Methods

Data on patients receiving ICI therapy from January 2016 to September 2022 were collected retrospectively. Patients were included if they had received an ICI or concurrent chemotherapy to treat a solid tumor or hematological malignancy at Peking Union Medical College Hospital. The ophthalmic diagnoses were confirmed by two ophthalmologists. Patients diagnosed with irAEs in our institution but who had previous ICI therapy at other hospitals were excluded. Medical records were reviewed in detail for cancer history, type of ICIs, time of irAEs onset and treatments received. Patients were included in the analysis if they were followed-up at least 6 months after the first dose of ICIs or if they developed irAEs.

This study was approved by the Institutional Review Board of Peking Union Medical College Hospital and complied with the Declaration of Helsinki. The study only involved the analysis of existing medical data and records. The information of all included patients was anonymized and unidentifiable. Therefore, the requirement for informed consent was waived.

Statistical analysis was performed using SPSS (version 20; IBM, Armonk, NY, USA). The normality of data distribution was confirmed with the Kolmogorov-Smirnov test. Continuous non-normally distributed data were presented as medians (first quartile, third quartile) and compared by non-parametric test. Categorical variables were analyzed by Fisher’s exact test or the chi-square test. A Kaplan-Meier survival curve was performed to show the survival probability. A p-value <0.05 was considered statistically significant.

Results

Data from 962 patients who had been treated with ICIs were collected (Table 1). Of these, 946 patients received PD-1 or/and PD-L1, and 16 patients received CTLA-4 monotherapy or combined with PD-1/PD-L1. The most common ICI used in this study was pembrolizumab (373; 38.8%), followed by tislelizumab (118; 12.3%), sintilimab (98; 10.2%), and camrelizumab (89; 9.3%). About half of the patients (477; 49.6%) had lung cancer. The median follow-up was 53 weeks. We identified 248 (25.8%) patients who developed irAEs, including 11 ophthalmic irAEs. The most common system affected by irAEs was endocrine (78, 31.5%), followed by skin (59, 23.8%) and lung (48, 19.4%). The first-year incidence rates of total irAEs and ophthalmic irAEs were 23.5% and 1.1%, respectively. The onset time of total irAEs ranged from one day to 106 weeks, with a median of 10 weeks (interquartile range 4-22 weeks). Ophthalmic irAEs occurred relatively earlier (median 5 weeks, interquartile range 2-7 weeks) (Figure 1).

Figure 1

Combination therapies of CTLA-4 and PD-1/PD-L1 resulted in higher incidences of total irAEs (42.9%) compared with monotherapy (27.6%) and ICIs plus chemotherapy (24.8%). However, no statistically significant differences were detected among these regimens (p = 0.218). Total irAEs were comparable among different ICIs (p = 0.341). Patients with lung cancer seemed to have a higher risk of irAEs. Out of 477 cases of lung cancer, 143 cases of irAEs (30%) were recorded, while of the remaining 485 cases of other cancers, 105 cases of total irAEs (21.6%) were recorded (p = 0.003). A similar difference was also found in ophthalmic irAEs (p = 0.032). Of the 11 recorded ophthalmic irAEs, 9 occurred in patients with lung cancer.

The age, gender, type of cancer, and ICI of 11 patients with ophthalmic irAEs are shown in Table 2. Only one patient was female. None had a previous history of ophthalmic inflammatory diseases. Nine patients had advanced lung cancer; the other two patients had colon cancer and esophageal squamous cell carcinoma, respectively. All patients received anti-PD-1 anti-bodies (four camrelizumab, four pembrolizumab, and singular sintilimab, tislelizumab, and nivolumab). The median time from starting ICI therapy to the onset of ophthalmic irAEs was 5 weeks (interquartile range 2-7 weeks). Nine patients had bilateral eye involvement. Eight patients had concomitant irAEs of other organs, mainly myositis and myocarditis.

Ophthalmoplegia was the most common ophthalmic irAE in this study (6/11). Ophthalmoplegia occurred a median of 4 weeks after the initiation of ICI treatment. Among these, three patients presented with ptosis, one patient had diplopia, and two suffered from both. Four patients had mucocutaneous involvement. Conjunctivitis was observed in three patients, with one of them having concomitant blepharitis. Patients with conjunctivitis had the shortest onset time of one week. All of these patients were treated with topical steroids for ocular surface inflammation. One patient had reactive cutaneous capillary endothelial proliferation (RCCEP) of the left eyelid after 2 cycles of camrelizumab. One patient in our cohort experienced orbital inflammation. He developed bilateral proptosis and periorbital edema 18 weeks after initiation of pembrolizumab treatment. Orbital MRI showed swelling of the orbital fat and periorbital tissue.

Eight patients had their ICIs discontinued immediately. One patient had camrelizumab discontinued 3 weeks later when his symptoms severely deteriorated after another ICI treatment cycle. The decision of discontinuation was made because of ophthalmic irAEs in two patients, because of extra-ophthalmic irAEs in three patients and because of both in four patients. The other two patients did not stop ICI therapy for their irAEs.

Three patients with ocular surface diseases received topical steroids. Ten patients with ophthalmic irAEs were treated with oral steroids. The initial dosage of oral steroids was 30-50 mg/day. Intravenous methylprednisolone (160-480 mg/day) was used in five patients before oral administration. The median duration of steroids treatment was 4.5 weeks (ranging from two weeks to four months). Four patients with severe extra-ophthalmic irAEs (myositis, myocarditis, and Steven-Johnson syndrome) received intravenous immunoglobulin (IVIG, 15-30g/day X 5 days) concurrently. Mycophenolate mofetil (0.75g bid) was administered to two patients.

At the end of the follow-up, ophthalmic irAEs were well controlled in ten out of eleven patients. Of these, eight patients had complete ophthalmologic remission, and two had partial remission. In terms of cancer control, three patients were in partial remission of neoplasia, one patient had stable disease, five patients’ cancers progressed. One patient died of uncontrolled myocarditis, the outcomes of ophthalmic irAEs and underlying cancer were not available.

Discussion

ICIs have become a powerful tool in the treatment of advanced malignancy, and their immune-related adverse events are very common (2). Most published research data were generated from the White populations (2, 3, 7). Ethnicity has also been reported as an important factor that influences ophthalmic irAEs (1). The percentage of uveitis-specific ophthalmic irAEs was higher in non-White patients (9.7% in Black patients) compared with 3.5% among White patients [3]. Ophthalmoplegia is more frequently detected in Asians than in Caucasians (1). In this study, we analyzed a cohort of the Chinese population and presented the incidence of total irAEs and ophthalmic irAEs.

Combination therapy with ICIs and chemotherapy or two types of ICIs are more beneficial for prolonging life expectancy in patients with metastatic malignancy, but they also result in a higher incidence of irAEs (8). A recent study reported that combination therapy (ICIs plus chemotherapy or two types of ICIs) caused a three- to four-fold increase in irAE risks (9). Our data showed a higher incidence of irAEs with CTLA4 and PD-1/PD-L1 combination therapy without statistical significance. CTLA4 inhibition results in a high incidence of dose-dependent toxicities, and 38.6-57.9% of patients with melanoma who received ipilimumab developed high-grade toxicities (10). While PD-1/PD-L1 antibodies cause high-grade irAEs in only 10–15% of patients (10). This is consistent with the fact that CTLA-4 blockade activates prime T cells throughout the body, whereas PD-1 and PD-L1 antibodies enhance peripheral antitumor immune cell activity more specifically (2). Combination therapy of ipilimumab has been shown to lead to a twice higher incidence of irAEs than monotherapy (11), which seems to be partially consistent with our data. However, the majority of our cohort received anti-PD-1/PD-L1 agents, only 16 patients had CTLA4 blockade treatment. We might have needed more cases with CTLA4 treatment to reach statistically meaningful conclusions.

Uveitis is considered to be the most common ophthalmic irAE (2, 8, 12, 13). However, we recorded no cases of uveitis in this cohort. To the best of our knowledge, most published cohorts contain large numbers of melanoma patients, ranging from 25.1–67% (14, 15). A registry study in Denmark reported 14 cases of ocular inflammation among 2190 cancer patients, with uveitis in nine out of these 14 cases, occurring among 550 melanoma patients (14). On the other hand, in a case series of ICI-related uveitis, the percentage of melanoma was as high as 76.15–86.7% (2, 6, 7, 16). Uveitis in melanoma patients is thought to be due to the cross reactivity of malignant melanoma cells and normal choroidal melanocytes (8, 16). Similarly, vitiligo is common in melanoma patients treated with ICIs (17), as the skin also contains many melanocytes. Sun et al. proposed that there may be an underlying difference in uveitis risk in patients with melanoma and non-melanoma malignancies (16). The incidence of melanoma is low in Asian populations. Our cohort had only two cases of melanoma. This may partially explain the absence of ICI-related uveitis in this study.

Despite several reports on ophthalmoplegia, it has not been considered a common irAE in previous case series. The most common neuromuscular irAE associated with ICIs is myositis (18, 19). Ocular symptoms, especially ptosis and diplopia, are frequent in ICI-related myositis (19, 20). In a recent study, Lin et al. found that ophthalmoplegia was the leading ophthalmic irAE in advanced lung cancer, accounting for 40.51% (1). The mechanism of neuromuscular irAEs remains unclear. Cancers with a high tumor mutational burden, such as non-small-cell lung cancer, have been associated with a higher risk of irAEs (21). One report documented that nine T-cell antigens shared between non-small cell lung cancer tissue and skin were identified, suggesting overlapping T-cell antigens as a mechanism for irAEs in lung cancer (22). Similarly, we propose that there might be cross antigens between non-small-cell lung cancer tissues and striated muscle.

Symptoms and signs of anterior uveitis can be mild, or even absent. In clinical practice, only patients with new onset eye complaints are likely to receive ophthalmic evaluation. Consequently, the incidence of uveitis might be underestimated. However, the symptoms of ophthalmoplegia can have a serious impact on the daily life of patients, making visiting the hospital timelier. Most cases of ICI-associated ophthalmoplegia in this study had concomitant myositis or myocarditis. Ophthalmologists should be well aware of these life-threatening underlying diseases.

The American Society of Clinical Oncology (ASCO) guidelines recommended that high-grade irAEs generally warrant discontinuation of ICIs and initiation of high-dose steroids (23). Severe and refractory cases may require infliximab or other immunosuppressive therapy. It is crucial that ophthalmologists and oncologists remain vigilant when irAEs are suspected, and carefully weigh the risks and benefits of discontinuing ICI therapy (2). Moreover, the mainstay of controlling irAEs is immunosuppression with steroids, and the long-term effects of high-dose steroids on cancer survivors have not been fully understood (6). We noted that most patients in this study responded well to topical and oral steroids. However, five patients had progressive disease after discontinuation of ICIs and initiation of steroids. Early recognition of ophthalmic irAEs can ensure adequate controls and possible lowering of their effects by prompt topical or oral steroid therapy, so that administration of life-prolonging ICIs can continue (16). In addition, one patient with orbital inflammation had his ICI agent continued, and his symptoms responded well to oral steroids, indicating that it is not necessary to routinely discontinue ICI therapy in patients who develop ICI-related ophthalmic disorders. The rechallenge of ICIs should be considered for patients with progressive neoplasia.

Pembrolizumab, nivolumab, atezolizumab and durvalumab have been authorized by the Food and Drug Administration (FDA) for numerous cancer therapies (24). Tislelizumab, sintilimab, camrelizumab and toripalimab are domestic anti-PD-1 monoclonal antibodies in China. Due to different study populations of clinical trials and a lack of head-to-head trials, comparisons of irAEs could not be made directly between these drugs in most cases (25). In a recent meta-analysis (26), an indirect comparison was conducted to evaluate sintilimab compared with other PD-1/PD-L1 antibodies, including pembrolizumab, atezolizumab, tislelizumab, camrelizumab and nivolumab. The results showed that any grade or grade ≥3 adverse event was comparable between these drugs. Similarly, in our Chinese cohort, total irAEs were comparable among different PD-1/PD-L1 inhibitors (p = 0.341). Our study may offer a choice for comparing the safety profile of these drugs.

Our study has several limitations. These patients were all referred for ophthalmic consultation by oncologists because of ophthalmic symptoms. Mild ophthalmic irAEs might have been neglected and not included in this study. The actual incidence of irAEs could be underestimated because of insufficient attention. In addition, this is a retrospective study in one center with a limited sample size. Only a few cases in our cohort underwent CTLA4 treatment. The exact relationship between different ICI agents and irAEs cannot be determined.

Conclusion

Combination therapy may increase the risk of irAEs. The spectrum of irAEs can be affected by ethnicity, cancer, or ICI agents. Ophthalmoplegia is the most common ophthalmic irAE in our Chinese cohort. Prompt recognition of ophthalmic irAEs and referral to an ophthalmologist are essential to ensure prompt diagnosis and close monitoring. Multidisciplinary consultation is crucial for optimal treatment and for determining whether to discontinue life-prolonging immunotherapy.

References

• 1

  ZhouLWeiX. Ocular immune-related adverse events associated with immune checkpoint inhibitors in lung cancer. Front Immunol (2021) 12:701951. doi: 10.3389/fimmu.2021.701951

  • CrossRef
  • Google Scholar

• 2

  FortesBHLiouHDalvinLA. Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo clinic experience. Br J Ophthalmol (2021) 105(9):1263–71. doi: 10.1136/bjophthalmol-2020-316970

  • CrossRef
  • Google Scholar

• 3

  SunMMKellySPMylavarapu BsALHollandGNColemanALYuFet al. Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American academy of ophthalmology intelligent research in sight registry. Ophthalmology (2021) 128(6):910–9. doi: 10.1016/j.ophtha.2020.11.001

  • CrossRef
  • Google Scholar

• 4

  BomzeDMeirsonTHasan AliOGoldmanAFlatzLHabot-WilnerZ. Ocular adverse events induced by immune checkpoint inhibitors: A comprehensive pharmacovigilance analysis. Ocul Immunol Inflamm (2022) 30(1):191–7. doi: 10.1080/09273948.2020.1773867

  • CrossRef
  • Google Scholar

• 5

  YoungLFinniganSStreicherHChenHXMurrayJSenHNet al. Ocular adverse events in PD-1 and PD-L1 inhibitors. J Immunother Cancer (2021) 9(7):e002119. doi: 10.1136/jitc-2020-002119

  • CrossRef
  • Google Scholar

• 6

  ShahzadOThompsonNClareGWelshSDamatoECorrieP. Ocular adverse events associated with immune checkpoint inhibitors: a novel multidisciplinary management algorithm. Ther Adv Med Oncol (2021) 13:1758835921992989. doi: 10.1177/1758835921992989

  • CrossRef
  • Google Scholar

• 7

  DowERYungMTsuiE. Immune checkpoint inhibitor-associated uveitis: Review of treatments and outcomes. Ocul Immunol Inflamm (2021) 29(1):203–11. doi: 10.1080/09273948.2020.1781902

  • CrossRef
  • Google Scholar

• 8

  NobleCWGangaputraSSThompsonIAYuanAApoloABLeeJMet al. Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocular Immunol inflammation. (2020) 28(6):854–9. doi: 10.1080/09273948.2019.1583347

  • CrossRef
  • Google Scholar

• 9

  HouYLWangDYHuJXTianRYWangWSuQet al. Risk of ophthalmic adverse events in patients treated with immune checkpoint inhibitor regimens: A systematic review and meta-analysis. Ocul Immunol Inflamm (2022) 30(6):1449–59. doi: 10.1080/09273948.2021.1890133

  • CrossRef
  • Google Scholar

• 10

  JohnsonDBNebhanCAMoslehiJJBalkoJM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol (2022) 19(4):254–67. doi: 10.1038/s41571-022-00600-w

  • CrossRef
  • Google Scholar

• 11

  WolchokJDChiarion-SileniVGonzalezRRutkowskiPGrobJJCoweyCLet al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med (2017) 377(14):1345–56. doi: 10.056/NEJMoa1709684

  • CrossRef
  • Google Scholar

• 12

  Alba-LineroCAlbaE. Ocular side effects of checkpoint inhibitors. Surv Ophthalmol (2021) 66(6):951–9. doi: 10.1016/j.survophthal.2021.01.001

  • CrossRef
  • Google Scholar

• 13

  KhanOFMonzonJ. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy. Curr Oncol (2020) 27(Suppl 2):S43–50. doi: 10.3747/co.27.5111

  • CrossRef
  • Google Scholar

• 14

  D’SouzaMBaggerMAlbertiMMalmborgMSchouMTorp-PedersenCet al. Immune checkpoint inhibitor treatment and ophthalmologist consultations in patients with malignant melanoma or lung cancer-a nationwide cohort study. Cancers (Basel). (2021) 14(1):49. doi: 10.3390/cancers14010049

  • CrossRef
  • Google Scholar

• 15

  ChaudotFSèvePRousseauAMariaATJFourniePLozachPet al. Ocular inflammation induced by immune checkpoint inhibitors. J Clin Med (2022) 11(17):4993. doi: 10.3390/jcm11174993

  • CrossRef
  • Google Scholar

• 16

  Sun Mm MdPLevinsonRMFilipowiczADAnesiSMKaplanHMWang W MdPet al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocular Immunol inflammation. (2020) 28(2):217–27. doi: 10.1080/09273948.2019.1577978

  • CrossRef
  • Google Scholar

• 17

  PotoRTroianiTCriscuoloGMaroneGCiardielloFTocchettiCGet al. Holistic approach to immune checkpoint inhibitor-related adverse events. Front Immunol (2022) 13:804597. doi: 10.3389/fimmu.2022.804597

  • CrossRef
  • Google Scholar

• 18

  MukhareshLChwaliszBK. Neuro-ophthalmic complications of immune-checkpoint inhibitors. Semin Ophthalmol (2021) 36(4):241–9. doi: 10.1080/08820538.2021.1890796

  • CrossRef
  • Google Scholar

• 19

  VermeulenLDepuydtCEWeckxPBechterOVan DammePThalDRet al. Myositis as a neuromuscular complication of immune checkpoint inhibitors. Acta Neurol Belg. (2020) 120(2):355–64. doi: 10.1007/s13760-020-01282-w

  • CrossRef
  • Google Scholar

• 20

  VogrigAMuñiz-CastrilloSFarinaAHonnoratJJoubertB. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. J Neurol (2022) 269(3):1701–14. doi: 10.1007/s00415-021-10870-6

  • CrossRef
  • Google Scholar

• 21

  BomzeDHasan AliOBateAFlatzL. Association between immune-related adverse events during anti-PD-1 therapy and tumor mutational burden. JAMA Oncol (2019) 5(11):1633–5. doi: 10.001/jamaoncol.2019.3221

  • CrossRef
  • Google Scholar

• 22

  BernerFBomzeDDiemSAliOHFässlerMRingSet al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol (2019) 5(7):1043–7. doi: 10.01/jamaoncol.2019.0402

  • CrossRef
  • Google Scholar

• 23

  BrahmerJRLacchettiCSchneiderBJAtkinsMBBrassilKJCaterinoJMet al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol (2018) 36(17):1714–68. doi: 10.200/JCO.2017.77.6385

  • CrossRef
  • Google Scholar

• 24

  ZhouYWXuQWangYXiaRLLiuJYMaXL. Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management. Int J Ophthalmol (2022) 15(4):646–56. doi: 10.18240/ijo.2022.04.19

  • CrossRef
  • Google Scholar

• 25

  ZhangLHaoBGengZGengQ. Toripalimab: the first domestic anti-tumor PD-1 antibody in China. Front Immunol (2021) 12:730666. doi: 10.3389/fimmu.2021.730666

  • CrossRef
  • Google Scholar

• 26

  ZhangLQianYLiJCuiCChenLQuSet al. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer. Future Oncol (2022) 18(15):1896–905. doi: 10.2217/fon-021-1336

  • CrossRef
  • Google Scholar